Disclosed are 2-(aryl)-4-oxo-quinazoline derivatives as represented by the general formula (II), wherein: X is N； R1 and R3 are each independently selected from alkoxy and hydrogen； R2 is selected from alkoxy, alkyl, and hydrogen； R6 and R8 are each independently selected from alkyl, alkoxy, chloride, and hydrogen； R5 is hydrogen； R7 is selected from amino, hydroxyl, alkoxy, and alkyl substituted with a heterocyclyl, or two adjacent substituents selected from R6, R7, and R8 are connected to form a heterocyclyl； R4 is hydrogen or is absent； each W is independently selected from C and N, wherein if W is N, then p is 0 or 1, and if W is C, then p is 1； with the proviso that if R2 is selected from alkoxy or hydrogen, then at least one of R1 and R3 is alkoxy； with the proviso that if R7 is selected from hydroxyl or alkoxy, then at least one of R6 and R8 are independently selected from alkyl, alkoxy, and chloride； with the proviso that if for W-(R7)p, W is N and p is 0, then at least one of R6 and R8 is chloride； and pharmaceutically acceptable salts and hydrates thereof. Representative compounds include 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one. Further disclosed is a pharmaceutical composition which comprises a compound as defined above and a pharmaceutically acceptable carrier for treating or preventing a cardiovascular cholesterol or lipid related disorder in a mammal, and particularly where said disorder is atherosclerosis.
